Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN-06: evorpacept in advanced HER2-overexpressing gastric or gastroesophageal junction adenocarcinoma
2023-509406-30-00Phase 3Completed
- Sponsor
- ALX Oncology
- Start
- Feb 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, randomised trial of evorpacept in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by ALX Oncology. Primary endpoints: Objective response rate and Overall survival. Started Feb 2024; status: completed.
02
Drugs
evorpacept
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-509406-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509406-30-00.